Healthy elderly, aged 55-70 years. Colostrum
Conditions
Interventions
Colosure (50 g), dissolved with 180 mL of water, taken orally, twice daily, for 12 weeks,Placebo (50 g), dissolved with 180 mL of water, taken orally, twice daily, for 12 weeks
Experimental Dietary Supplement,Placebo Comparator Dietary Supplement
Colosure dietary supplement product,Placebo
Sponsors
Program Management Unit for Competitiveness (PMUC)
Wellnovations Co., Ltd.
Eligibility
Sex/Gender
All
Age
55 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age between 55-70 years 2. Weight of at least 40.0 kg and body mass index within the range of 18.5-22.9 kg/m2 3. General good health 4. Normal cognitive function or mild cognitive impairment 5. Able to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Presence of any severe co-morbidity(ies), uncontrolled medical condition(s), or medical illness(es) 2. History of body metal implants or brachytherapy 3. History of hypersensitivity to any ingredients in the investigational product 4. Any other condition(s) in which any ingredients in the investigational product are contraindicated 5. Any other condition(s) that affects swallowing or consumption of the investigational product 6. Problem(s) with alcoholism, substance abuse, or heavy smoking 7. Use of a medication(s), herb(s), dietary supplement(s), or vitamin(s) that is likely to interact with any ingredients in the investigational product 8. Receives a vaccine(s) within 14 days (for inactivated vaccines) or 30 days (for live vaccines) or plan to receive any vaccines during the study period 9. Participates in another clinical trial concurrently or within 30 days 10. Plan to have a baby, or known or suspected pregnancy, or breastfeeding (for female patients)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immune parameters 0, 4, 12 weeks Levels of immunoglobulins; Leukocyte counts and/or leukocyte subsets; and Levels of serum cytokines/inflammatory markers | — |
Secondary
| Measure | Time frame |
|---|---|
| Upper respiratory tract infection-related symptoms and other infections 0-12 weeks Upper respiratory tract infection-related symptoms and other infections,Body composition assessment 0, 12 weeks Muscle mass and bone mass,Bone markers 0, 12 weeks P1NP, osteocalcin or beta-CrossLaps,Cognitive function 0, 12 weeks TMSE and MoCA,Safety 0-12 weeks Safety assessment | — |
Countries
Thailand
Contacts
Public ContactNut Koonrungsesomboon
Chiang Mai University
Outcome results
None listed